Funder: Pfizer Inc.
Due Dates: April 22, 2026 (Submission deadline, full application — 23:59 EST; late applications not reviewed)
Funding Amounts: Up to $100,000 CAD per project; total budget $300,000 CAD; max project length 1.5 years
Summary: Supports educational initiatives and resources to improve management and support for ALK+ mNSCLC patients on TKI therapy, emphasizing multidisciplinary and patient-centered approaches.
Key Information: Applicant organizations must be based in Canada; only organizations (not individuals) are eligible.